Hon. Robin Rosenberg

Robin Lee Rosenberg (born January 22, 1962) is a United States district judge of the United States District Court for the Southern District of Florida and former Florida circuit court judge.

Education and Career

Rosenberg received a Bachelor of Arts degree in 1983 from Princeton University. She received a Master of Arts degree and Juris Doctor in 1989 from Duke University and Duke University School of Law. 

She began her legal career as a law clerk to Judge James C. Paine of the United States District Court for the Southern District of Florida from 1989 to 1990. She served as a trial attorney in the Civil Rights Division of the United States Department of Justice from 1990 to 1994. While on leave from that position, she worked at a non profit organization in the Czech Republic from 1993 to 1994. She was an associate at the law firm of Foley & Lardner from 1994 to 1995. She served as an assistant city attorney for the City of West Palm Beach, Florida, from 1995 to 1997. She was a partner at Holland & Knight LLP, from 1997 to 1999. She served as vice president and general counsel at the Slim Fast Foods Company from 1999 to 2001. She was a partner at the law firm of Rosenberg & McAuliffe, PL, from 2001 to 2006, and concurrently managed ARC Mediation, a full service dispute resolution firm, from 2002 to 2006. From 2007 to 2014, she was a circuit court judge in the Fifteenth Judicial Circuit.

Rosenberg is married to former Florida State Attorney for Palm Beach County Michael McAuliffe.

Federal Judicial Service

On February 26, 2014, President Barack Obama nominated Rosenberg to serve as a United States District Judge of the United States District Court for the Southern District of Florida, to the seat vacated by Judge Adalberto Jordan. She received her judicial commission on July 24, 2014.

Notable Cases

• 2022, Presided over the federal Zantac litigation. She issued an order that resulted in the dismissal of thousands of claims brought by individuals diagnosed with cancer, after the Court granted the drug makers’ motion to exclude expert testimony that plaintiffs’ maintain establishes toxic chemicals in the recalled heartburn drug caused their diagnosis.